Product Overview
[Drug name]
Generic name: Dapoxetine hydrochloride tablets
Trade name: AiTingJiu Dapoxetine hydrochloride tablets 30mg*6 tablets
Pinyin full code: AiTingJiu YanSuanDaBoXiTingPian 3Omg*6Pian
[Main ingredients]
Dapoxetine hydrochloride.
[Indications/main functions]
Applicable to the treatment of male premature ejaculation (PE) patients aged 18 to 64 who meet all of the following conditions: 1. Continuous or repeated ejaculation due to minimal sexual stimulation before, during or shortly after the penis is inserted into the vagina, and before sexual satisfaction is obtained; 2. Significant personal distress or interpersonal communication disorders caused by premature ejaculation (PE); 3. Poor ejaculation control ability.
[Specifications]
30mg*6 tablets
【Dosage and Administration】
Oral. The tablet should be swallowed whole. Patients are advised to take the drug with at least a full glass of water. Patients should try to avoid injuries caused by prodromal symptoms such as syncope or dizziness. 1. The recommended first dose for all patients in adult males (18 to 64 years old) is 30 mg, which needs to be taken about 1 to 3 hours before sexual intercourse. If the effect after taking 30 mg is not satisfactory and the side effects are still within the acceptable range, the dose can be increased to the maximum recommended dose of 60 mg. The recommended maximum dose frequency is once every 24 hours. This product can be taken before or after meals (see the pharmacokinetics section). If the doctor chooses this product to treat premature ejaculation, the risks and patient-reported benefits should be evaluated in the first 4 weeks of treatment with this drug, or the risk-benefit balance of the patient should be evaluated after 6 treatment doses and a decision should be made whether to continue the treatment with this product. 2 Elderly (65 years and above) The safety and efficacy of this product in patients aged 65 and above has not been evaluated, mainly because the data on the use of this product in this population is extremely limited (see the pharmacokinetics
[Adverse Reactions]
Syncope (characterized by loss of consciousness) has been reported in clinical trials and is considered to be drug-related. Most cases occurred within 3 hours of dosing, after the first dose, or during study-related procedures performed in the clinic (such as blood draws, upright maneuvers, and blood pressure measurements). Syncope is often preceded by prodromal symptoms. Orthostatic hypotension has been reported in clinical trials. The most common (≥5%) adverse drug reactions in clinical trials include headache, dizziness, nausea, diarrhea, insomnia, and fatigue. The most common events leading to discontinuation include nausea and dizziness.
[Contraindications]
This product is contraindicated for use in patients with known allergies to dapoxetine hydrochloride or any excipients.
